What Happened?
Burnaby, BC-based MSI Appointed Barry Guld as Chief Executive Officer
About the Company
MSI Methylation Sciences Inc. (“MSI”) is a clinical-stage pharmaceutical company focused on developing new products based on molecules which have clinical proof of concept but which have yet to be exploited in the major pharmaceutical markets. MSI`s focus is in the CNS space where clinical proof of concept is key to reducing the drug development risk. Our lead product candidate, Strada™, is based upon Ademetionine, a naturally occurring molecule produced throughout the body, where it plays a vital role in the one-carbon cycle. Our disease indication is Major Depressive Disorder (MDD).
About the Person
Barry Guld is Chief Executive Officer at MSI. Previously, Barry held various senior HR leadership roles in the industry.
Info Source
News
Short Profile